Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: T2 Biosystems; Devyser, Genoks, Velsera

NEW YORK — Swedish diagnostics firm Devyser said this week that it has secured a tender from an unidentified university hospital in Stockholm for Devyser Thalassemia, a next-generation sequencing-based screening and confirmation test for thalassemia, a hereditary blood disorder. The tender is initially for two years and may be extended for another two years. The annual order value of the tender is about SEK 2.1 million ($2.1 million), Devyser said. 

T2 Biosystems announced this week that it has executed a territory-exclusive distribution agreement in Hong Kong and Macau. Under the terms of the agreement, T2 Biosystems will sell the T2Dx instrument, along with the T2Bacteria, T2Candida, and T2Resistance panels through the newly appointed distributor. Financial terms of the agreement were not disclosed. 

Turkish genomics healthcare company Genoks and precision medicine-focused informatics firm Velsera said they are collaborating to advance cancer diagnostics and treatment in Turkey and nearby regions. The partnership combines Genoks' genomic expertise with Velsera's Clinical Genomics Workspace (CGW), a platform designed for comprehensive analysis of data obtained from solid tissue and liquid tumor as well as hematological cancer samples. Genoks will integrate CGW into its cancer diagnostic services, enhancing its ability to detect and characterize various types of cancer accurately, the companies said. 

In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on 360Dx.